Last updated: September 4, 2026
Dasiglucagon hydrochloride, marketed in the United States as Zegalogue by Zealand Pharma, is an emergency glucagon analog for severe hypoglycemia in adults and children aged 6 years and older with diabetes. Its commercial value depends on adoption of ready-to-use rescue products, competition from Baqsimi and Gvoke, payer coverage, and Zealand Pharma’s ability to expand distribution beyond its initial direct-commercialization model.
Zegalogue has FDA approval and commercial availability, but it remains a niche product within the broader diabetes market. The main commercial challenge is converting patients from inexpensive emergency glucagon kits and established competing devices. The main strategic asset is the product’s ready-to-use delivery format and potential for use by caregivers without reconstitution.
What is dasiglucagon hydrochloride and how does Zegalogue work?
Dasiglucagon is a synthetic glucagon analog that raises blood glucose by stimulating hepatic glycogen breakdown. Zegalogue is supplied as a 0.6 mg subcutaneous injection in a prefilled syringe and an autoinjector.
| Attribute |
Dasiglucagon hydrochloride |
| Brand |
Zegalogue |
| Developer |
Zealand Pharma A/S |
| Active ingredient |
Dasiglucagon |
| Therapeutic area |
Diabetes and severe hypoglycemia |
| FDA application |
NDA 214231 |
| FDA approval |
March 22, 2021 |
| Approved population |
Adults and pediatric patients aged 6 years and older |
| Dose |
0.6 mg subcutaneously |
| Repeat dose |
May be repeated after 15 minutes if needed |
| Delivery |
Prefilled syringe and autoinjector |
| Regulatory pathway |
New drug application |
| Primary market |
United States |
The product is intended for emergency treatment, not routine glucose management. Its commercial positioning is based on ease of administration, storage convenience and caregiver usability relative to traditional glucagon emergency kits, which require mixing before injection. The FDA-approved label identifies nausea, vomiting, injection-site reactions and headache among the principal adverse reactions. (U.S. Food and Drug Administration, 2021)
What is the FDA regulatory status of dasiglucagon?
Zegalogue is FDA-approved and marketed in the United States. The approval covers treatment of severe hypoglycemia in patients with diabetes who are at least 6 years old.
The FDA approval did not establish dasiglucagon as a first-line therapy for all hypoglycemic events. Its use is directed at severe episodes in which the patient cannot safely consume oral carbohydrates or requires caregiver intervention.
The regulatory profile has three commercial implications:
- The product has an established prescription pathway and can be covered through pharmacy benefits.
- The product is used primarily for emergency preparedness, so utilization is linked to prescriptions per patient rather than frequent monthly dosing.
- Prescribers often select among several rescue products based on device design, formulary position, patient education and caregiver preference.
Zegalogue’s approval is narrower than the total potential market for glucagon rescue products because its labeled pediatric indication begins at age 6. The company has not established a broad U.S. label for children younger than 6 years.
How large is the dasiglucagon and emergency glucagon market?
The addressable market is the population with diabetes at meaningful risk of severe hypoglycemia, rather than the full diabetes population. High-risk segments include patients using intensive insulin therapy, children with type 1 diabetes, patients with impaired hypoglycemia awareness and individuals with recurrent severe events.
The market has shifted from traditional emergency glucagon kits toward ready-to-use delivery systems:
| Product |
Company |
Delivery format |
Principal competitive attribute |
| Zegalogue |
Zealand Pharma |
Autoinjector and prefilled syringe |
Ready-to-use dasiglucagon analog |
| Baqsimi |
Lilly |
Nasal powder |
Needle-free administration |
| Gvoke |
Xeris Biopharma |
Autoinjector and prefilled syringe |
Ready-to-use liquid glucagon |
| Glucagon emergency kits |
Multiple manufacturers |
Reconstitution injection |
Lower-cost, established option |
Eli Lilly’s Baqsimi established nasal glucagon as a commercially important alternative to injectable rescue products. Xeris’s Gvoke created direct competition in ready-to-use liquid glucagon. Traditional generic glucagon kits remain relevant because they are inexpensive and widely recognized by physicians and payers. (Eli Lilly and Company, 2019; Xeris Biopharma, 2019)
The market therefore has three distinct purchasing propositions:
- lowest acquisition cost through conventional glucagon kits;
- needle-free administration through Baqsimi;
- ready-to-use injectable delivery through Zegalogue and Gvoke.
Zegalogue competes most directly with Gvoke on device format and with Baqsimi on caregiver convenience.
How does Zegalogue compare with Baqsimi and Gvoke?
Zegalogue’s differentiation is pharmacological and device-based, but neither attribute creates a fully protected commercial segment.
| Factor |
Zegalogue |
Baqsimi |
Gvoke |
| Active agent |
Dasiglucagon |
Glucagon |
Glucagon |
| Administration |
Subcutaneous injection |
Intranasal |
Subcutaneous injection |
| Reconstitution required |
No |
No |
No |
| Needle-free |
No |
Yes |
No |
| Pediatric labeling |
Age 6 and older |
Age 4 and older |
Age 12 and older for certain presentations, with label details dependent on product and jurisdiction |
| Main commercial advantage |
Ready-to-use analog formulation |
Needle-free use |
Ready-to-use liquid glucagon |
| Main commercial barrier |
Injectable device and limited scale |
Nasal administration limitations and formulary competition |
Competitive access and commercial scale |
Baqsimi has a meaningful advantage in caregiver acceptance because it eliminates needles. Gvoke has a longer commercial presence in the ready-to-use injectable category and benefits from Xeris’s proprietary liquid formulation technology. Zegalogue’s strongest position is in patients and caregivers who prefer an autoinjector or prefilled syringe but do not want to prepare a conventional glucagon kit.
The products are substitutes at the point of prescribing, but they are not clinically identical. Device usability, speed of administration, patient age, insurance coverage and caregiver training can determine the selected product.
What is the financial trajectory for dasiglucagon and Zealand Pharma?
Zegalogue has generated commercial revenue, but it has not become the primary financial driver of Zealand Pharma. Zealand’s financial trajectory has been shaped more heavily by partnerships, milestone payments and the value of its broader peptide pipeline than by Zegalogue product sales alone.
The product’s financial profile has four stages:
| Period |
Commercial phase |
Financial characteristics |
| 2021 |
U.S. launch |
Initial commercialization costs, market access investment and limited prescribing history |
| 2022 |
Expansion of distribution |
Greater pharmacy and payer reach, but intense competition from Baqsimi and Gvoke |
| 2023 |
Portfolio integration |
Product revenue remained strategically relevant but was smaller than partnership-driven corporate revenue |
| 2024 onward |
Mature niche product phase |
Growth depends on refill persistence, formulary access, channel expansion and international rights |
Public company reporting does not consistently present Zegalogue as a large standalone revenue line with the same level of detail used for Zealand’s collaboration revenue. This limits precise public measurement of product-level sales, margins and contribution to operating profit.
The commercial economics are structurally less attractive than those of chronic diabetes medicines because:
- a prescription is often held for emergency use;
- repeat utilization is low;
- patients may retain a product beyond the normal replacement cycle;
- insurance deductibles can make branded rescue products expensive;
- generic kits exert price pressure;
- three branded alternatives compete for the same prescription.
Zegalogue can produce recurring revenue through replacement prescriptions, school and caregiver stocking, and multiple-device prescriptions. It is unlikely to match the revenue scale of a high-volume chronic diabetes therapy without a major expansion in market share or indication breadth.
What patents protect dasiglucagon hydrochloride and Zegalogue?
Zegalogue is protected through a combination of active-ingredient, formulation, delivery-device and method-of-use rights. The commercial value of this estate depends on the scope and enforceability of each claim, not simply on the number of granted patents.
The principal protection categories are:
Active-ingredient patents
These cover dasiglucagon and related glucagon analog structures. Composition claims can provide the strongest barrier when they read directly on the approved active pharmaceutical ingredient.
Formulation patents
Dasiglucagon is supplied as a stable injectable formulation. Formulation claims may cover pH, excipients, concentration, stability and storage conditions. These rights are important because an entrant may seek to avoid the active-ingredient estate by using a different formulation.
Device and presentation patents
Zegalogue’s prefilled syringe and autoinjector presentations can be protected through device, container, cartridge, needle, activation and packaging claims. Device patents generally provide narrower protection than composition patents because an entrant may design around individual mechanical elements.
Method-of-use patents
Use claims may cover emergency treatment of severe hypoglycemia, patient populations, dosing and administration. Their practical value depends on whether an entrant markets a competing product for the same indication and whether induced-infringement theories are available.
Public patent databases and FDA listing records should be reviewed together because issued patents, Orange Book-listed patents and enforceable patent claims are not identical categories. Patent term adjustment, terminal disclaimers, pediatric extensions and patent ownership changes can affect the final expiration date.
What is the Orange Book status of Zegalogue?
Zegalogue is an FDA-approved prescription drug, and the relevant Orange Book record is the principal public reference for listed patents and regulatory exclusivity associated with the approved product.
Orange Book analysis should distinguish among:
- patents listed for the approved NDA;
- patents that may cover the active ingredient but are not listed;
- patents covering formulations or devices;
- regulatory exclusivity that has already expired;
- patent terms that remain enforceable after regulatory exclusivity ends.
Zegalogue’s five-year new chemical entity exclusivity began with the 2021 approval and would generally run through March 2026, subject to the specific statutory calculation and any applicable adjustments. This period restricts submission of certain abbreviated applications that rely on the NDA. It does not create a permanent barrier to a follow-on product.
Because Zegalogue contains a novel glucagon analog and uses a specialized delivery presentation, follow-on developers may evaluate both an abbreviated pathway and a 505(b)(2) pathway. The regulatory route will depend on product sameness, clinical bridging requirements, formulation differences and the patents listed for the reference product.
When does dasiglucagon lose exclusivity?
The first major regulatory exclusivity milestone is the expected end of five-year new chemical entity exclusivity in March 2026. Patent protection may extend beyond that point.
The practical loss-of-exclusivity sequence is likely to follow this pattern:
| Milestone |
Expected commercial effect |
| March 2026 |
End of standard five-year NCE exclusivity, subject to statutory calculation |
| Post-2026 |
Potential abbreviated or 505(b)(2) filings if regulatory and patent conditions are satisfied |
| Patent expiration |
Potential launch of products that avoid or invalidate remaining patent claims |
| Litigation resolution |
Earlier or later entry depending on settlement terms, injunctions and court rulings |
| Post-entry period |
Price erosion and payer-driven substitution |
No public evidence establishes that a biosimilar pathway is the main threat to Zegalogue. Dasiglucagon is a chemically defined peptide drug rather than a conventional monoclonal antibody biologic. The more relevant risks are an ANDA or 505(b)(2) product, a competing glucagon formulation, or a device-based alternative.
Which companies are challenging the Zegalogue franchise?
The principal competitive pressure comes from commercial products rather than publicly prominent patent challengers.
Eli Lilly
Lilly’s Baqsimi is the strongest branded alternative for patients and caregivers seeking needle-free rescue. Its nasal delivery system gives Lilly a differentiated route of administration and broad physician awareness.
Xeris Biopharma
Xeris’s Gvoke is the closest commercial competitor by delivery format. Its ready-to-use liquid glucagon technology directly competes with the practical convenience offered by Zegalogue.
Generic manufacturers
Generic drug companies can challenge the franchise through conventional glucagon emergency kits or, after applicable exclusivity and patent barriers, through a product designed to rely on the Zegalogue NDA or a related regulatory pathway.
Potential 505(b)(2) developers
A developer could pursue a modified glucagon or glucagon-analog product using published safety and efficacy information while generating additional studies for formulation, device or route-of-administration differences. Such a product would still face patent and labeling risks.
What patent litigation and Paragraph IV risks affect dasiglucagon?
A Paragraph IV challenge would allege that a listed patent is invalid, unenforceable or not infringed. The filing could trigger patent litigation and a 30-month stay of FDA approval for the challenged application, subject to the statutory framework and litigation events.
For Zegalogue, the most relevant future challenge targets would likely include:
- active-ingredient patents;
- stable liquid formulation patents;
- autoinjector or prefilled-syringe patents;
- method-of-use patents tied to severe hypoglycemia;
- patents covering storage or presentation conditions.
The litigation risk is commercially meaningful after the end of NCE exclusivity because an entrant may accept litigation costs in exchange for an earlier launch. The risk is lower if the core active-ingredient claims extend well beyond 2026 and are difficult to design around.
Publicly documented, high-profile Paragraph IV litigation against Zegalogue was not a major market driver through mid-2024. The absence of a prominent challenge does not eliminate future risk. The most likely entry strategy may involve a formulation or delivery design that avoids the broadest claims rather than a direct copy of Zegalogue.
What generic launch scenarios exist for Zegalogue?
Three launch scenarios are commercially plausible.
Scenario one: delayed entry after patent expiry
A follow-on product launches after relevant patents expire. Price erosion is gradual because emergency glucagon prescriptions remain brand-sensitive and payers may retain multiple products.
Scenario two: negotiated early entry
Zealand reaches a settlement that permits a generic or follow-on product to launch before the latest patent expiration. The settlement could include a date-certain entry, supply terms or restrictions on the product presentation.
Scenario three: successful Paragraph IV challenge
A challenger invalidates or avoids key patents and launches earlier. This would create the highest risk to Zegalogue’s price and prescription share.
The impact would depend on whether the entrant is a conventional glucagon kit, a ready-to-use injectable, a nasal product or a dasiglucagon-equivalent product. Direct substitution would be greatest from a ready-to-use product with equivalent labeling and comparable reimbursement.
How strong is the dasiglucagon patent estate?
The estate is potentially strongest around the active analog and stable injectable formulation. Device patents add commercial protection but are more vulnerable to design-around strategies.
| Protection layer |
Relative strength |
Main vulnerability |
| Dasiglucagon composition |
High if broad and unexpired |
Invalidity or non-infringement arguments |
| Injectable formulation |
Moderate to high |
Alternative excipients or concentrations |
| Autoinjector |
Moderate |
Device redesign |
| Prefilled syringe |
Moderate |
Alternative presentation |
| Method of use |
Moderate |
Labeling and induced-infringement limits |
| Packaging and storage |
Low to moderate |
Different packaging or stability profile |
The estate’s strength depends on claim breadth, patent term, prosecution history and whether the marketed product practices the asserted claims. A large patent count alone would not establish a strong barrier.
What licensing deals support the dasiglucagon market?
Zealand Pharma has used licensing and partnership transactions across its broader pipeline, but Zegalogue has primarily remained a Zealand-controlled commercial product in the United States. The company’s strategic model has emphasized internal commercialization of selected products while using partners for other peptide programs.
This structure gives Zealand control over pricing, branding and market access for Zegalogue. It also leaves the company responsible for sales infrastructure, payer negotiations, inventory, field promotion and post-launch commercial execution.
A regional licensing deal or commercialization partnership could improve Zegalogue’s economics outside the United States, but the product’s current value is concentrated in emergency glucagon markets where competing branded products already have established distribution.
What is the geographic coverage of dasiglucagon?
The United States is the principal commercial market for Zegalogue. Global opportunity is constrained by regulatory approvals, reimbursement differences and the presence of local glucagon products.
Geographic expansion would require:
- country-specific regulatory submissions;
- local pricing and reimbursement agreements;
- pediatric labeling alignment;
- cold-chain or storage validation;
- local device and packaging compliance;
- commercial distribution or licensing partners.
The value of international expansion is highest in markets with strong insulin penetration, organized diabetes care and reimbursement for emergency rescue products. The product’s commercial performance outside the United States would depend heavily on whether it can obtain a differentiated reimbursement position against nasal and traditional injectable glucagon.
Key Takeaways
- Dasiglucagon hydrochloride is marketed as Zegalogue for severe hypoglycemia in adults and children aged 6 years and older.
- FDA approval was granted on March 22, 2021, under NDA 214231.
- The principal competitors are Lilly’s Baqsimi and Xeris’s Gvoke, along with low-cost conventional glucagon kits.
- The product’s commercial differentiation is ready-to-use injectable administration, not a monopoly over emergency glucagon treatment.
- Five-year new chemical entity exclusivity is expected to reach its principal milestone around March 2026, while patent protection may continue beyond that date.
- Generic risk is more likely to arise through an ANDA or 505(b)(2) strategy than through a biosimilar pathway.
- Zegalogue has generated commercial revenue but has not been the main financial driver of Zealand Pharma’s corporate results.
- The strongest intellectual-property layers are likely the active analog and stable injectable formulation. Device and method-of-use claims are more susceptible to design-around strategies.
- Revenue growth depends on formulary access, caregiver preference, replacement prescriptions and share capture from Baqsimi, Gvoke and traditional glucagon kits.
FAQs about dasiglucagon hydrochloride
Is dasiglucagon the same as glucagon?
No. Dasiglucagon is a synthetic glucagon analog designed for emergency glucose elevation. Traditional glucagon products contain glucagon itself.
Is Zegalogue a biologic or a generic drug?
Zegalogue is an FDA-approved prescription drug containing a synthetic peptide analog. It is not a biosimilar. A follow-on product may require an ANDA or 505(b)(2) application depending on its formulation, device and clinical differences.
Can Zegalogue be used in children?
Yes. The FDA-approved indication covers pediatric patients aged 6 years and older with diabetes who experience severe hypoglycemia.
Which product competes most directly with Zegalogue?
Gvoke is the closest competitor by ready-to-use injectable format. Baqsimi is the most important alternative for needle-free administration.
What is the primary commercial risk for Zegalogue?
The main risk is limited prescription growth caused by competing branded rescue products, low-cost glucagon kits, payer restrictions and the infrequent-use nature of emergency hypoglycemia medicines.
References
-
Eli Lilly and Company. (2019). Baqsimi glucagon nasal powder prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2021). Zegalogue (dasiglucagon) injection prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2021). FDA approves first ready-to-use glucagon rescue pen for severe hypoglycemia. U.S. Department of Health and Human Services.
-
Xeris Biopharma Holdings, Inc. (2019). Gvoke glucagon injection prescribing information. U.S. Food and Drug Administration.
-
Zealand Pharma A/S. (2024). Annual report 2023. Copenhagen, Denmark: Zealand Pharma A/S.
